Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK

Background: In two previous studies we investigated the association between the rs1414334 C/G and 759 C/T polymorphisms in the HTR2C gene, coding for the 5HT2c-receptor, and prevalence of the metabolic syndrome in a schizophrenic population. In both studies we found an association between the variant rs1414334 C-allele and an increased prevalence of the metabolic syndrome. Objectives: The objective of the current study was to try to replicate our previous findings in a different patient sample. Methods: Patients were included from an ongoing ' Pharmacotherapy Monitoring and Outcome survey'. A crosssectional design was used to investigate the association between HTR2C variants and the metabolic syndrome in patients diagnosed with schizophrenia or related disorders. Patients ≥18 years, using antipsychotics, were eligible for inclusion. Primary endpoint was prevalence of the metabolic syndrome. Primary determinants were the 759 C/Tand rs1414334:C>G polymorphisms in the X-linked HTR2c gene. The association between carriership of the variant HTR2C alleles and prevalence of the metabolic syndrome was investigated with logistic regression. Data were investigated for potential confounding effects of age, ethnicity, diagnosis, sex, SSRI's and antipsychotics. Results: 186 patients, mainly male (68%) and Caucasian (93%) were included. Age, sex, antipsychotic drugs, use of SSRI's and DSM-IV diagnosis were confounders and included in the multi-variate analysis. The variant rs1414334 C-allele, but not the variant 759-T allele, was significantly associated with the metabolic syndrome (Adjusted OR 3.99; 95%CI 1.40-11.33). Conclusions: This study confirms our previous findings that the variant rs1414334 C-allele is associated with the metabolic syndrome.